secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-007086
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics appoints Malte Peters CEO as founder Barbara Weber becomes Executive Chair; cash $343M
--------------------------------------------------------------------------------

- Barbara Weber, M.D. retires as President and CEO effective Jan 8, 2026; becomes Executive Chair through 2026.
- Malte Peters, M.D., board member since 2018, named President and CEO; granted 1.65M options and 350K RSUs.
- Cash, cash equivalents and marketable securities totaled $343M as of Dec 31, 2025 (unaudited).
- 2026 milestones reiterated: vopimetostat combos data, lung cancer update, pancreatic pivotal start, TNG456 data.
- Alexis Borisy transitions from Board Chair to Lead Independent Director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526007086/0001193125-26-007086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526007086/d26323d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-007086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer